Drawing for QUOTIENT MOSAIQ

USPTO serial 86178447

QUOTIENT MOSAIQ

Reviewed by CopyMark Law Group

Reg. 4820521Status 710
Filing date
Status date
Registration date
Sep 29, 2015
Examiner
SOBRAL, CHRISTINA
Law office
TMEG LAW OFFICE 109

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with QUOTIENT MOSAIQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Stacey J. Watson, Esq.

Stacey J. Watson, Esq. Markery Law LLCP.O. Box 84150Gaithersburg, MD 20883-4150UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Diagnostic preparations for scientific or research use provided as part of a kit; test kits consisting of diagnostic preparations for scientific or research use; diagnostic reagents and diagnostic reagents for analytical, scientific and industrial use; diagnostic assay preparation, namely, assays, for scientific, industrial and research purposesSECTION 8 - CANCELLED—
005Diagnostic reagents derived from blood or in-vitro culture for medical diagnostic purposes; protein based microarrays for medical diagnostic purposes in the nature of antigen typing and antibody identification, blood grouping and disease screening; protein based microarrays for in-vitro testing for medical diagnostic purposes; diagnostic reagents for medical use; chemical reagents for medical diagnosis and analysis; diagnostic assay preparations in the nature of assays and substances in the nature of reagents for blood grouping and disease screening for clinical and medical use; medical diagnostic reagents for testing blood, blood components and plasma for clinical and medical use; medical diagnostic reagents for clinical and medical use as control agents for in vitro diagnostic tests; medical diagnostic reagents for clinical and medical use for virology screening for donor blood; medical diagnostic assays for clinical and medical use for antigen typing and antibody identification, blood grouping and disease screening; diagnostic preparations and kits comprised of medical diagnostic reagents for sensitivity testing, quality control and proficiency testing in relation to diagnostic techniques, processes and instruments, all for clinical medical useSECTION 8 - CANCELLED—
009Scientific research and laboratory apparatus for diagnostic testing in the nature of antigen typing and antibody identification, blood grouping and disease screening; Laboratory equipment, namely, microarrays; none of the aforesaid relating to electronic medical records and software for electronic medical recordsSECTION 8 - CANCELLED—
010Medical diagnostic testing instruments for blood typing; Medical diagnostic testing instruments for screening blood and blood products; Medical diagnostic testing instruments for antigen typing; Medical diagnostic testing instruments for antibody identification, blood grouping and disease screening; microarrays in the form of medical testing instruments for in-vitro testingSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 8, 2022C8..CANCELLED SEC. 8 (6-YR)—
Jul 10, 2021COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Jul 9, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 12, 2021ES7RTEAS SECTION 7 REQUEST RECEIVED—
Sep 29, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 23, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 23, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 23, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 23, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 23, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 29, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 14, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 24, 2015NPUBNOTICE OF PUBLICATION—
Jun 9, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 3, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 3, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 3, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 27, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Mar 3, 2015CNSLLETTER OF SUSPENSION MAILED—
Mar 3, 2015CNSLSUSPENSION LETTER WRITTEN—
Mar 2, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 1, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 1, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 2, 2014CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 1, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 6, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 6, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 30, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 5, 2014CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 5, 2014DOCKASSIGNED TO EXAMINER—
Feb 14, 2014AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Feb 12, 2014ALIEASSIGNED TO LIE—
Feb 10, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 6, 2014ALIEASSIGNED TO LIE—
Feb 5, 2014PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Feb 1, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance